Shancheng Ren
Shanghai Changzheng Hospital · Changhai Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shancheng Ren as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:54 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06895811 · Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPCShanghai Changzheng Hospital · active not recruiting · Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer · principal investigator
- Early Ph1NCT06866548 · Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate CancerShanghai Changzheng Hospital · active not recruiting · mCRPC · principal investigator
- Early Ph1NCT06586658 · Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal CellsShanghai Changzheng Hospital · suspended · Renal Cell Carcinoma · principal investigator
- Ph1NCT04053062 · LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate CancerBioray Laboratories · suspended · Castrate-Resistant Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:54 UTC. The ranking covers the 200 most relevant of 129 PubMed records, and a shared surname and initials can bring in a namesake. All 129 on PubMed
- 3,498 citationsRCR 88.2
- 391 citationsRCR 10.4
- Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.Cancer Immunol Res · 2019292 citationsRCR 9.5
- Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.J Thorac Oncol · 2022284 citationsRCR 16.2
- 228 citationsRCR 11.8
- 208 citationsRCR 5.7
- HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.Ann Oncol · 2019173 citationsRCR 5.5
- Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.J Clin Pharmacol · 2007121 citationsRCR 3.0
- Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology.Int J Gynecol Cancer · 2003112 citationsRCR 3.0
- A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.Hepatology · 2017112 citationsRCR 4.0